• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.22% Nasdaq Up0.53%

    T. Rowe Price Health Sciences (PRHSX)

    62.81 Down 0.12(0.19%) May 26

    Profile as of Apr 29, 2016Get Profile for:
    T. Rowe Price Health Sciences
    T. Rowe Price Health Sciences Fund, Inc.100 East Pratt StreetBaltimore MD 21202
    Map
    Phone: 800-638-5660
    Fund Overview 
    Category:Health
    Fund Family:T. Rowe Price
    Net Assets:11.80B
    Year-to-Date Return:-10.70%
    Yield:0.00%
    Morningstar Rating:5 stars
    Fund Inception Date:Dec 29, 1995
    Morningstar Style Box 
    Health
    [View Category Definition]
    View Top Health Funds
    About the Morningstar Style Box
    Management Information 
    Taymour R. Tamaddon
    Lead Manager since Feb 15, 2013
    Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad earned a bachelor of medical science undergraduate degree with first-class honors from the University of Nottingham and a bachelor of medicine, bachelor of surgery (M.D.) from the University of Nottingham Medical School. He also holds the Chartered Financial Analyst designation.
    Investment Information 
    Min Initial Investment:2,500
    Min Initial Investment, IRA:1,000
    Min Initial Investment, AIP:2,500
    Min Subsequent Investment:100
    Min Subsequent Investment, IRA:100
    Min Subsequent Investment, AIP:100
    PRHSX can be purchased from 120 brokerages.

    Fund Summary 
    The investment seeks long-term capital appreciation. The fund will normally invest at least 80% of its net assets (including any borrowings for investment purposes) in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed "health sciences"). While the fund can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-capitalization companies.

    Fund Operations 
    Last Dividend : 0.00
    Last Cap Gain (Dec 14, 2015) : 0.00
    Annual Holdings Turnover (May 25, 2016) : 31.00%
    Average for Category:44.87%
    Fees & Expenses 
    ExpensePRHSXCategory Avg
    Annual Report Expense Ratio (net):0.76%1.32%
    Prospectus Net Expense Ratio:0.76%N/A
    Prospectus Gross Expense Ratio:0.76%N/A
    Max 12b1 Fee:0.00%N/A
    Max Front End Sales Load:N/A5.30%
    Max Deferred Sales Load: N/A2.31%
    3 Yr Expense Projection*:243595
    5 Yr Expense Projection*:422863
    10 Yr Expense Projection*:9421,704
    * Per $10,000 invested